Hereditary transthyretin (hATTR) amyloidosis is a rare progressive disease that is passed from parent to child. It is caused by a mutant form of the transthyretin (TTR) protein that can damage ...

Wainua (eplontersen) is a prescription injection medicine that slows down nerve damage in people with a type of amyloidosis called hereditary transthyretin-mediated amyloidosis (hATTR). The FDA ...

As the name suggests, hereditary transthyretin amyloidosis (hATTR) with polyneuropathy runs in families. If you have it, you got it from genes one or both of your parents passed to you.

She noted that hATTR amyloidosis can affect several parts of the body, namely the somatic nervous system (nerve damage leading to a range of symptoms, including loss of voluntary movement of the ...

Alnylam is using Twitter and a new website to run a European-based awareness campaign for a rare condition known as hereditary ATTR (hATTR) amyloidosis. | Alnylam is using Twitter and a new ...

Dublin, June 24, 2019 (GLOBE NEWSWIRE) -- The 'Market Spotlight to 2027: Amyloidosis' report has been added to ResearchAndMarkets.com'... A vertical stack of ...

The road trip trope is alive and well in medical marketing, as Alnylam Pharmaceuticals recently utilized the motif to raise awareness of hereditary ATTR (hATTR) amyloidosis. Last week, the ...

There are two different forms of ATTR amyloidosis — hereditary ATTR (hATTR) amyloidosis, which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ...

NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.

Alnylam Canada ULC is pleased to announce that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of AMVUTTRA® (vutrisiran ...

New study published in the BMJ Open calls for major shift in the management of hATTR amyloidosis Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced.